Trial Profile

A Prospective, Post-marketing, Non-interventional Study of RISankizumab Evaluating Real-world Clinical Effectiveness in Crohn's Disease (APPRISE)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risankizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms APPRISE
Sponsors AbbVie

Most Recent Events

06 Apr 2025 Planned End Date changed from 1 Jan 2028 to 1 Jul 2028.
06 Apr 2025 Planned primary completion date changed from 1 Jan 2028 to 1 Jul 2028.
10 Dec 2024 Planned End Date changed from 31 Jan 2028 to 1 Jan 2028.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com